Cargando…

Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results

BACKGROUND: Early treatment with tranexamic acid may reduce deaths after traumatic brain injury (TBI). In mild and moderate TBI, there is a time to treatment interaction, with early treatment being most beneficial. Time to treatment was recorded by clinicians and is subject to error. Using monitorin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansukhani, Raoul, Frimley, Lauren, Shakur-Still, Haleema, Sharples, Linda, Roberts, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382791/
https://www.ncbi.nlm.nih.gov/pubmed/32711551
http://dx.doi.org/10.1186/s13063-020-04623-5
_version_ 1783563318427910144
author Mansukhani, Raoul
Frimley, Lauren
Shakur-Still, Haleema
Sharples, Linda
Roberts, Ian
author_facet Mansukhani, Raoul
Frimley, Lauren
Shakur-Still, Haleema
Sharples, Linda
Roberts, Ian
author_sort Mansukhani, Raoul
collection PubMed
description BACKGROUND: Early treatment with tranexamic acid may reduce deaths after traumatic brain injury (TBI). In mild and moderate TBI, there is a time to treatment interaction, with early treatment being most beneficial. Time to treatment was recorded by clinicians and is subject to error. Using monitoring data from the CRASH-3 trial, we examine the impact of errors in time to treatment on estimated treatment effects. METHODS: The CRASH-3 trial was a randomised trial of the effect of tranexamic acid on death and vascular occlusive events in 12,737 TBI patients. This analysis includes the 8107 patients with a Glasgow coma scale score of 9 to 15 since previous analyses showed that these patients benefit most from early treatment. Clinician-recorded time to treatment was checked against ambulance and hospital records for 1368/12,737 (11%) patients. Patients who died were preferentially selected for monitoring and we monitored 36% of head injury deaths. We describe measurement errors using Bland-Altman graphs. We model the effect of tranexamic acid on head injury death using logistic regression with a time-treatment interaction term. We use regression calibration, multiple imputation and Bayesian analysis to estimate the impact of time to treatment errors. RESULTS: Clinicians rounded times to the nearest half or full hour in 66% of cases. Monitored times were also rounded and were identical to clinician times in 63% of patients. Times were underestimated by an average of 9 min (95% CI − 85, 66). There was more variability between clinician-recorded and monitored times in low- and middle-income countries than in high-income countries. The treatment effect estimate at 1 h was greater for monitored times OR = 0.61 (95% CI 0.47, 0.81) than for clinician-recorded times OR = 0.63 (95% CI 0.48, 0.83). All three adjustment methods gave similar time to treatment interactions. For Bayesian methods, the treatment effect at 1 h was OR = 0.58 (95% CI 0.43, 0.78). Using monitored times increased the time-treatment interaction term from 1.15 (95% CI 1.03, 1.27) to 1.16 (95% CI 1.05, 1.28). CONCLUSIONS: Accurate estimation of time from injury to treatment is challenging, particularly in low resource settings. Adjustment for known errors in time to treatment had minimal impact on the trial results. TRIAL REGISTRATION: ClinicalTrials.gov NCT01402882. Registered on 25 July 2011
format Online
Article
Text
id pubmed-7382791
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73827912020-07-27 Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results Mansukhani, Raoul Frimley, Lauren Shakur-Still, Haleema Sharples, Linda Roberts, Ian Trials Research BACKGROUND: Early treatment with tranexamic acid may reduce deaths after traumatic brain injury (TBI). In mild and moderate TBI, there is a time to treatment interaction, with early treatment being most beneficial. Time to treatment was recorded by clinicians and is subject to error. Using monitoring data from the CRASH-3 trial, we examine the impact of errors in time to treatment on estimated treatment effects. METHODS: The CRASH-3 trial was a randomised trial of the effect of tranexamic acid on death and vascular occlusive events in 12,737 TBI patients. This analysis includes the 8107 patients with a Glasgow coma scale score of 9 to 15 since previous analyses showed that these patients benefit most from early treatment. Clinician-recorded time to treatment was checked against ambulance and hospital records for 1368/12,737 (11%) patients. Patients who died were preferentially selected for monitoring and we monitored 36% of head injury deaths. We describe measurement errors using Bland-Altman graphs. We model the effect of tranexamic acid on head injury death using logistic regression with a time-treatment interaction term. We use regression calibration, multiple imputation and Bayesian analysis to estimate the impact of time to treatment errors. RESULTS: Clinicians rounded times to the nearest half or full hour in 66% of cases. Monitored times were also rounded and were identical to clinician times in 63% of patients. Times were underestimated by an average of 9 min (95% CI − 85, 66). There was more variability between clinician-recorded and monitored times in low- and middle-income countries than in high-income countries. The treatment effect estimate at 1 h was greater for monitored times OR = 0.61 (95% CI 0.47, 0.81) than for clinician-recorded times OR = 0.63 (95% CI 0.48, 0.83). All three adjustment methods gave similar time to treatment interactions. For Bayesian methods, the treatment effect at 1 h was OR = 0.58 (95% CI 0.43, 0.78). Using monitored times increased the time-treatment interaction term from 1.15 (95% CI 1.03, 1.27) to 1.16 (95% CI 1.05, 1.28). CONCLUSIONS: Accurate estimation of time from injury to treatment is challenging, particularly in low resource settings. Adjustment for known errors in time to treatment had minimal impact on the trial results. TRIAL REGISTRATION: ClinicalTrials.gov NCT01402882. Registered on 25 July 2011 BioMed Central 2020-07-25 /pmc/articles/PMC7382791/ /pubmed/32711551 http://dx.doi.org/10.1186/s13063-020-04623-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mansukhani, Raoul
Frimley, Lauren
Shakur-Still, Haleema
Sharples, Linda
Roberts, Ian
Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
title Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
title_full Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
title_fullStr Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
title_full_unstemmed Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
title_short Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
title_sort accuracy of time to treatment estimates in the crash-3 clinical trial: impact on the trial results
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382791/
https://www.ncbi.nlm.nih.gov/pubmed/32711551
http://dx.doi.org/10.1186/s13063-020-04623-5
work_keys_str_mv AT mansukhaniraoul accuracyoftimetotreatmentestimatesinthecrash3clinicaltrialimpactonthetrialresults
AT frimleylauren accuracyoftimetotreatmentestimatesinthecrash3clinicaltrialimpactonthetrialresults
AT shakurstillhaleema accuracyoftimetotreatmentestimatesinthecrash3clinicaltrialimpactonthetrialresults
AT sharpleslinda accuracyoftimetotreatmentestimatesinthecrash3clinicaltrialimpactonthetrialresults
AT robertsian accuracyoftimetotreatmentestimatesinthecrash3clinicaltrialimpactonthetrialresults